Page 11 - Serum Institute Of India

Govt to provide Rs 4,500 cr to vaccine manufacturers to ramp up capacity

Looking to ramp up supplies ahead of the opening of Covid vaccination to all citizens over 18 years of age, the government has approved a payment of about Rs 4,500 crore as advance to vaccine makers

India hopeful US will soon end curbs on Covid vaccine raw materials export

The White House has invoked the wartime powers of the Defense Production Act to preserve vaccine raw materials for its own companies

Govt fast-tracks Covid-19 fight, to start vaccination for 18+ from May 1

States allowed to procure directly from manufacturers; open market supply permitted

Serum, Bharat Biotech to get suppliers' credit for 300 mn Covid-19 doses

Govt okays Rs 4,500 cr upfront payment for 300 mn doses

Expanding vaccine supply

Some good moves but freer pricing needed

Govt push to step up Covid-19 vaccine output 10 times by September

Bharat Biotech and 3 PSEs to ramp up Covaxin production capacity

SII CEO urges US to lift raw material export ban to up vaccine production

Adar Poonawalla on Friday said the US needs to lift its embargo on raw material exports

India fast-tracks emergency use of foreign-made Covid-19 vaccines

No need for prior local clinical trials for vaccines cleared by regulators

Covid-19 vaccine Sputnik V gets DCGI nod; may be available by May

Russian Covid-19 vaccine granted restricted emergency-use authorisation in India

Right prescription

Fast-tracking of vaccine approvals is a welcome policy change

Centre says problem is not of Covid vaccine shortage but of planning

'On one hand, we have states like Kerala where there is zero wastage (of vaccine) and on the other hand, we have several other states where there still is 8-9% of wastage,' says Union Health Secretary

Expert panel recommends approval to Russia's Sputnik V Covid-19 vaccine

Now, the Drugs Controller General of India DCGI will consider this recommendation and decide whether to grant Sputnik V approval for restricted emergency use in India

Covid-19 vaccine: Real-world data to decide commercial marketing approval

Two such vaccines are Covishield, made by the Serum Institute of India (SII), and Covaxin by Bharat Biotech

Failure on vaccines

Refusal to support private sector has led to a roll-out flop

Will stop Serum's vehicles if doses not given to Maharashtra: Raju Shetti

He claimed people in Maharashtra are angry over not getting the vaccine, and many vaccination centres are closed due to the shortage of doses

Covid-19 vaccination sites drop to half in India amid shortage of doses

Number of locations down from 120,000 to 60,000 from April 3 to 7

Serum Institute is legally bound to supply Covid-19 vaccines: COVAX

SII partner AstraZeneca has already issued it a legal notice over delays to other shipments, even as many Indian states have complained of a shortage facing priority recipients.

Is it safe? Global concern over the use of AstraZeneca vaccine explained

In India, Serum Institute of India is manufacturing AstraZeneca's vaccine under the brand Covishield

'Equitable distribution': Covax says Serum bound to supply virus vaccines

India could resume vaccine exports by June, the firm's chief executive, Adar Poonawalla, told media this week

WHO rejects SII's proposal for extension of Covishield's shelf life: Report

The WHO has rejected Serum Institute of India's proposal seeking extension of the shelf life of Oxford-AstraZeneca Covid-19 vaccine, Covishield, from six to nine months, citing insufficient data